Sanofi Reports Results of Sarclisa (isatuximab) in P-III IKEMA trial in Patients with Relapsed Multiple Myeloma
Shots:
- The P-III trial involves assesing of Sarclisa (IV- 10mg/kg qw for four weeks) in combination with carfilzomib (20/56mg/m2- bid) and dexamethasone in 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries
- The study resulted in meeting its 1EP and resulted in the reduction of risk of disease progression or death with no new safety signals observed
- Sarclisa is a mAb involves binding with specific epitope on the CD38 receptor- currently evaluated in P-III in combination with standard treatments for multiple myeloma and has also received positive CHMP opinion in combination with pomalidomide + dexamethasone for 2L+ R/R MM
Click here to read full press release/ article | Ref: Sanofi | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com